论文部分内容阅读
目的探讨进展期胃癌术中行区域性缓释化疗的安全性。方法 2005年1月—2007年1月收治的进展期胃癌89例,随机分为区域性缓释化疗组45例采用常规治疗联合区域性缓释化疗,对照组40例采用常规治疗观察两组近期、远期观察指标。结果两组1年生存率比较P>0.05无显著差异性。两组2、3年生存率比较P<0.05有显著差异性。结论应用区域性缓释化疗能够有效的起到对癌细胞的杀灭作用,减少复发延长患者的生命。对局部应用安全性较高,与对照组进行比较除了腹腔引流量大以外,没有增加手术的并发症及合并症的发生。总之,进展期胃癌术中行区域性缓释化疗是安全、可靠、方便、疗效确切,值得临床应用。
Objective To investigate the safety of regional delayed-release chemotherapy in advanced gastric cancer. Methods 89 patients with advanced gastric cancer admitted to our hospital from January 2005 to January 2007 were randomly divided into regional sustained-release chemotherapy group (n = 45) treated by conventional therapy combined with regional controlled-release chemotherapy and control group (n = 40) treated by conventional therapy , Long-term observation indicators. Results 1-year survival rate of two groups compared P> 0.05 no significant difference. Two and three-year survival rates were significantly different P <0.05. Conclusion The application of regional sustained-release chemotherapy can effectively kill the cancer cells and reduce the recurrence and prolong the life of patients. The safety of the local application of high, compared with the control group in addition to a large abdominal drainage, there is no increase in the incidence of complications and complications. In short, advanced gastric cancer surgery in the line of regional sustained-release chemotherapy is safe, reliable, convenient, effective, it is worth clinical application.